HIFU Hyperthermia With Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric and Young Adult Solid Tumors
Status:
Withdrawn
Trial end date:
2019-03-16
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether Doxil (liposomal doxorubicin) given prior
to MR-HIFU Hyperthermia is safe for the treatment of pediatric and young adult patients with
recurrent and refractory solid tumors.